Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Activation effects of chidamide on BET signaling pathways and the mechanism of  synergistic effect with BET inhibitors in Mantle Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLi FuJSJing Shen

Discussion

Loading...

Member takes

Overview

Experimental findings demonstrate chidamide enhances cytotoxicity and cell cycle arrest in mantle cell lymphoma, indicating potential for epigenetic therapy.

Key Points

  • To explore the mechanism of chidamide's effects on BET signaling pathways and its synergistic role with BET inhibitors in mantle cell lymphoma.
  • Assessment of HDAC1, HDAC2, and HDAC6 expression in MCL patients' samples
  • Cytotoxicity evaluation of chidamide using CCK-8 assay
  • Determination of IC50 for chidamide and JQ1 treatments
  • Western blot analysis for protein expression levels
  • Evaluation of cell cycle arrest in treated MCL cell line (Maver-1)
  • Chidamide exhibited an IC50 of 0.9 μM after 48 hours in Maver-1 cells
  • High expression of HDAC1 and low expression of HDAC6 observed in MCL tissues
  • Combination of chidamide and JQ1 resulted in significant G2/M phase arrest
  • Evidence of synergistic effects on disrupting the cell cycle in MCL cells
  • Potential modulation of the immune microenvironment linked to treatment effects

Cite This Study

Fu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5cahttps://doi.org/10.1182/blood-2025-7053
View Full Paper
Ask AI
Bookmark
Share